Structure Therapeutics Inc. American Depositary Shares GPCR · USD
Health Care · US listing · 🇺🇸 United States
21.41
+5.21%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Structure Therapeutics Inc. American Depositary Shares
From its filings with the US Securities and Exchange Commission
Structure Therapeutics Inc. American Depositary Shares is based in South San Francisco, California and is incorporated in Cayman Islands. Its shares trade on Nasdaq under the ticker GPCR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $141.2m. At that date it held total assets of $1.58bn and shareholders' equity of $1.52bn.
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.
Obesity is a complex, heterogeneous, chronic, and progressive disease, which substantially affects health, quality of life and mortality. “Obesity” and “severe obesity” are defined by a body mass index (“BMI”) of greater than 30 and 40 kg/m2, respectively, with abnormal or excessive fat accumulation. “Overweight” is defined by a BMI of greater than 25 kg/m2.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2023
- Employees
- 220
- Website
- structuretx.com ↗
- Head office
- 601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GSBR-1290 is in phase 2 trials for obesity treatment in the US market.
- Structure Therapeutics has 220 employees focused on clinical stage biopharmaceuticals.
- ACCGR-2671 is in phase 1 trials for obesity treatment targeting amylin receptors.
Weaknesses
- The company has no products approved for market yet.
- All clinical trials are in early stages with no phase 3 results available.
- Limited financial resources as a clinical stage biopharmaceutical company.
Opportunities
- GSBR-1290 could address unmet needs in obesity treatment in the US.
- ACCGR-2671 may expand obesity treatment options with amylin receptor targeting.
- GIPR program offers potential for dual GLP-1R/GIPR agonist therapies in obesity.
Threats
- Competition from established obesity drug therapies in the US market.
- Regulatory delays could impact phase 2 trial timelines for GSBR-1290.
- High costs of clinical trials may strain financial resources further.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.